Table 2.
Search terms on adverse outcomes and health effects including MIEs and KEs used in AOP helpFinder search.
| MeSH Terms | Other Search Terms |
|---|---|
| Infant, Small for Gestational Age | Amino acids |
| Infant, Small for Gestational Age/growth and development | Nutrients |
| Infant, Small for Gestational Age/blood | Glucose |
| Infant, Small for Gestational Age/metabolism | Fatty acids |
| Infant, Small for Gestational Age/physiology | Fetal growth restriction |
| Premature Birth | Intrauterine growth retardation |
| Pre-Eclampsia | Intrauterine growth restriction |
| Receptor, Fibroblast Growth Factor, Type 1 | Placenta malperfusion |
| Placenta Diseases | Vascular endothelial growth factor |
| Placenta Growth Factor | Flt-1 |
| Placenta Growth Factor, PLGF-1 Isoform | Thiol adduct |
| Receptors, Vascular Endothelial Growth Factor | Thio/seleno-protein |
| Receptors, Androgen | Oxidative stress |
| Receptors, Estrogen | DNA polymerase gamma |
| Small for Gestational Age | |
| Small for Gestational Age/growth and development | |
| Small for Gestational Age/blood | |
| Small for Gestational Age/metabolism | |
| Small for Gestational Age/physiology | |
| Fetal growth restriction | |
| Intrauterine growth retardation | |
| Intrauterine growth restriction | |
| IUGR | |
| Inhibition Cytochrome P450 enzyme activity | |
| Inhibition CYP17A1 activity | |
| Decreased Aromatase mRNA | |
| Decreased Cyp19a1 mRNA | |
| Fetal growth | |
| AO | Increase, Growth inhibition |
| AO | Growth, reduction |
| AO | Decrease, Growth |
| MIE | Inhibition, VegfR2 |
| KE | Decreased, angiogenesis |
| KE | Defect of Embryogenesis |
| KE | Decrease, Growth |
| KE | Reduction, Progesterone synthesis |
| Oxidative stress | |
| MIE | Activation, NRF2 |
| KE | ROS formation |
| KE | Increase, Oxidative Stress |
| KE | Activation, PMK-1 P38 MAPK |
| KE | Down Regulation, GSS and GSTs gene |
| KE | Glutathione synthesis |
| KE | Glutathione homeostasis |
| MIE | Thiol group of chemicals interact with sulfhydryl groups of proteins to form thiol adducts |
| MIE | Inhibition of mitochondrial DNA polymerase gamma |
| KE | Dysfunction, Mitochondria |
| MIE | Binding, Thiol/seleno-proteins involved in protection against oxidative stress |
| Signaling pathways | |
| KE | Activation, AKT2 |
| KE | Activation, HIF-1 |
| KE | Activation, JAK/STAT pathway |
| KE | Activation, TGF-beta pathway |
| KE | Activation, JNK |
| MIE | Wnt ligand stimulation |
| KE | Inhibition, Wnt pathway |
| KE | Frizzled activation |
| KE | Alteration, Wnt pathway |
| Endocrine related pathways | |
| MIE | Activation, Androgen receptor |
| MIE | Decreased, Androgen receptor activity |
| MIE | Activation, Estrogen receptor |
| KE | Increased, Estrogen receptor activity |
| KE | Increased, ER activity |
| KE | Decrease, testosterone synthesis |
| KE | Decrease, testosterone level |
| KE | Decrease, dihydrotestosterone level |
| KE | Decrease, DHT level |
| KE | Decrease, androgen receptors (AR) activation |
| KE | Decrease, AR activation |
| KE | Reduction, 17-OH-pregnenolone conversion in DHEA |
| KE | Reduction, 17-OH-progesterone conversion in androstenedione |
| KE | Thyroid hormone disruption |
| Others | |
| MIE | Inhibition, Cytochrome P450 enzyme (CYP17A1) activity |
| MIE | Binding of substrate, endocytic receptor |
| MIE | Inhibition, Aromatase |
| KE | Decreased, Aromatase (Cyp19a1) mRNA |
| KE | Perturbation of cholesterol |
| KE | GSK3beta inactivation |
| KE | β-catenin activation |
Abbreviations: AO, adverse outcome; MIE, molecular initiating event; KE, key event.